Global Commercialization Plan Clause Samples
The Global Commercialization Plan clause outlines the framework and requirements for how a product or service will be marketed, distributed, and sold across multiple international markets. Typically, this clause details the responsibilities of each party in developing, approving, and implementing a comprehensive commercialization strategy, including timelines, target markets, and performance metrics. Its core function is to ensure both parties are aligned on the approach to global market entry and expansion, thereby reducing misunderstandings and facilitating coordinated efforts for successful international commercialization.
Global Commercialization Plan. The Joint Commercialization Committee shall develop and approve an initial Global Commercialization Plan at least [***] years prior to the anticipated [***]. After adoption of the initial Global Commercialization Plan, the Joint Commercialization Committee shall review the Global Commercialization Plan and approve any revisions or changes to the Global Commercialization Plan at least [***] for the following [***]. For clarity, the Global Commercialization Plan shall include high level guidelines regarding global strategies, goals and standards, but not the specific activities to be undertaken by each Party or budgets for such activities to achieve such goals. Each Party shall use good faith efforts to Commercialize Licensed Products in a manner consistent with the Global Commercialization Plan and Global Branding Strategy. If a Party becomes aware of any Commercialization activity conducted by such Party or any of its Affiliates, licensees or Sublicensees that materially deviates from the Global Commercialization Plan or Global Branding Strategy, it shall promptly notify the other Party of such deviation.
Global Commercialization Plan. Not later than [***] after the exercise by GSK of a GSK Program Option, GSK will prepare and provide to the JSC for review and consideration a draft global commercialization plan (to include, but not be limited to, the United States) with respect to the relevant GSK Development Compound (the “Global Commercialization Plan”). The Global Commercialization Plan will outline the strategic commercial objectives for the Product brand in each geographical region, product positioning [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. aspirations, pricing and reimbursement strategy, anticipated launch timings, the expected competitive landscape for the Product and initial sales and volume forecasts with key assumptions and sensitivities. During the development of the Global Commercialization Plan and subsequent Commercialization activities, OncoMed may appoint a marketing manager at its own expense to work with the GSK commercial team to receive information from and to provide information to the GSK commercial team. GSK will consider in good faith any comments on the draft Global Commercialization Plan provided by OncoMed. After GSK has received OncoMed’s comments on the draft Global Commercialization Plan, GSK will prepare a revised version of the Global Commercialization Plan.
Global Commercialization Plan. Reasonably in advance of the first Regulatory Approval for the first Optioned Product within a Collaboration Program, the Commercial Lead shall prepare for the JPT’s discussion, review and finalization a Global Commercialization Plan for such Collaboration Program in reasonable scope, as well as a corresponding Commercialization Budget for such Global Commercialization Plan that complies with the requirements of this Agreement. The JPT shall present such plan to the JSC for approval. The JPT shall agree upon the appropriate level of detail to be included in the respective Global Commercialization Plan; provided that if Denali has exercised the Denali Worldwide Royalty Option with respect to such Collaboration Program, the Global Commercialization Plan shall be limited to material Commercialization activities in Major Markets with a high-level budget for such activities.
Global Commercialization Plan. Reasonably in advance of the first Regulatory Approval for the first Product within each Program, Sanofi shall prepare for the JSC’s review and comment a Global Commercialization Plan for Products within such Program. Such plan shall include: (a) an outline for the strategy for the Commercial launch of, and subsequent Commercialization of, each such Product in at least the Major Markets; (b) a summary of pre-launch Commercialization activities to be taken, including procurement of any necessary pricing and governmental reimbursement approvals for each such Product in at least the Major Markets; (c) general marketing and promotional plans for each such Product worldwide; and (d) an estimated annual sales forecast for such Products worldwide. The JSC shall agree upon the appropriate level of detail to be included in the respective Global Commercialization Plan, but the Global Commercialization Plan does not need to duplicate the content of any Co-Commercialization Plan.
Global Commercialization Plan. Reasonably in advance of the first Regulatory Approval for the first Cost-Profit Sharing Product, Biogen shall prepare for the JCC’s review a Global Commercialization Plan for Cost-Profit Sharing Products. Such plan shall consist of: [***].
Global Commercialization Plan. On an annual basis, the Commercialization Committee shall approve a Global Commercialization Plan, which outlines the overall strategy and plan for the Commercialization of each Collaboration Product. Pharmacia shall prepare and submit to the Commercialization Committee for its review and approval each such Global Commercialization Plan. The Global Commercialization Plan shall be updated as deemed necessary but at least annually by Pharmacia.
Global Commercialization Plan. Following LB-001 Option Exercise, reasonably in advance of the anticipated date of the first Regulatory Approval for LB-001 [**], LogicBio will deliver to the LB-001 JSC for review a written plan setting forth [**] planned for LB-001 outside of Greater China, as appropriate given the stage of Development of LB-001 at such time (such plan, as may be amended from time to time in accordance with this Section 6.2.3(c) (Global Commercialization Plan), the “Global Commercialization Plan for LB-001”). From time to time thereafter, LogicBio will deliver proposed amendments to the Global Commercialization Plan for LB-001 to the LB-001 JSC for review. The LB-001 JSC shall have no right to approve the Global Development Plan for LB-001 but LogicBio shall take any comments provided by the LB-001 JSC into good faith consideration. [**].
Global Commercialization Plan. The JCC shall discuss a comprehensive, multi-year written global Commercialization plan (the “Global Commercialization Plan”) and subject to Section 5.3.1 to ensure alignment between the Parties on commercial strategy in the Territory and in the Vir Bio Territory. No later than [***], Vir Bio shall prepare and submit to the JCC a proposed initial Global Commercialization Plan for the Licensed Products in the Field. The initial Global Commercialization Plan shall be subject to review and discussion by the JCC (subject to the decision-making procedures set forth in Section 7.9). The initial Global Commercialization Plan and each annual update of the Global Commercialization Plan shall cover a period of [***]. The Global Commercialization Plan shall include [***].
Global Commercialization Plan. Not later than [***] after the exercise by GSK of a GSK Program Option, GSK will prepare and provide to the JSC for review and consideration a draft global commercialization plan (to include, but not be limited to, the United States) with respect to the relevant GSK Development Compound (the “Global Commercialization Plan”). The Global Commercialization Plan will outline the [***]. During the development of the Global Commercialization Plan and subsequent Commercialization activities, OncoMed may appoint a marketing manager at its own expense to work with the GSK commercial team to receive information from and to provide information to the GSK commercial team. GSK will consider in good faith any comments on the draft Global Commercialization Plan provided by OncoMed. After GSK has received OncoMed’s comments on the draft Global Commercialization Plan, GSK will prepare a revised version of the Global Commercialization Plan.
Global Commercialization Plan. On an annual basis, the Collaboration Committee shall approve a Global Commercialization Plan which outlines the overall strategy and plan for the Commercialization of each Collaboration Product. The portion of the Global Commercialization Plan for Collaboration Products for the RA Indication and any Other Indications (excluding any Celltech Other Indication) shall be prepared by Pharmacia and the portion of the Global Commercialization Plan for a Collaboration Product for the IBD Indication and Celltech Other Indication shall be prepared by Celltech. The Global Commercialization Plan shall be in accordance with customary standards for a product of comparable market potential. The Global Commercialization Plan shall be updated as deemed necessary but at least annually by the Parties, in consultation with each other, and submitted for review and approval to the Collaboration Committee. The initial Global Commercialization Plan shall be adopted by the Collaboration Committee no later than December 31, 2002.